Trial
NCT07100938
A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
BeiGene
Collaborators
—
Condition
Rheumatoid Arthritis
Intervention
BGB-45035
Why stopped
Sponsor has concluded that patients are unlikely to derive sufficient benefit from treatment with BGB-45035 to support continuation of the clinical development program due to unfavored benefit/risk profile.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-28